Pharmacodynamics

Correct Answer

C — Warfarin

Rationale

Warfarin has a narrow therapeutic index: the anticoagulant dose is only modestly below the dose that causes serious bleeding, and the therapeutic range is tightly defined by the international normalized ratio. Individual variation from diet, drug interactions, and genetic differences in metabolism and target enzyme expression means that plasma effect monitoring is mandatory. Amoxicillin and most other penicillins have therapeutic indices in the hundreds, making toxicity not realistically achievable at clinical doses. Metformin and atorvastatin also have wide therapeutic indices and do not require plasma concentration monitoring for efficacy or safety titration.

Correct Answer

A — Furosemide

Rationale

Furosemide is a loop diuretic that inhibits the sodium-potassium-chloride cotransporter in the thick ascending limb of the loop of Henle, where approximately 25% of filtered sodium is normally reabsorbed. This gives it a substantially higher maximum diuretic effect (Emax) than thiazide and thiazide-like diuretics including hydrochlorothiazide, chlorthalidone, indapamide, and metolazone, which act on the distal convoluted tubule and account for a smaller fraction of sodium reabsorption. The three distractors are all thiazide-type diuretics in the same class as hydrochlorothiazide and share a similar Emax ceiling.

Correct Answer

B — Lithium

Rationale

Lithium has a narrow therapeutic index with a target serum concentration of 0.6 to 1.2 milliequivalents per liter for maintenance therapy. Toxicity, manifesting as tremor, confusion, and in severe cases seizures and cardiac arrhythmias, begins to appear at concentrations above 1.5 milliequivalents per liter. This small separation between therapeutic and toxic concentrations places lithium firmly in the narrow therapeutic index category and mandates regular plasma level monitoring. Quetiapine, lamotrigine, and aripiprazole are used in mood disorders but do not require plasma concentration monitoring for routine dosing and have substantially wider margins between therapeutic and toxic exposure.

Correct Answer

D — Digoxin

Rationale

Digoxin has a narrow therapeutic index with a therapeutic serum concentration of 0.5 to 0.9 nanograms per milliliter for heart failure management. At concentrations above 2.0 nanograms per milliliter, toxicity produces a wide range of arrhythmias — from bradycardia and atrioventricular block to potentially fatal ventricular arrhythmias — along with nausea, visual disturbances, and confusion. Periodic serum digoxin levels and electrocardiographic monitoring are standard. Metoprolol, lisinopril, and amlodipine are cardiovascular drugs with substantially wider safety margins that do not require plasma concentration monitoring for routine management.

Correct Answer

A — Both are full agonists with the same maximum efficacy but different potencies

Rationale

Morphine and codeine are both full agonists at the mu-opioid receptor. As full agonists, both can produce the system maximum response — they share the same Emax for analgesia at saturating receptor occupancy. They differ substantially in potency: morphine is approximately ten times more potent than codeine on a milligram basis, meaning it achieves the same degree of analgesia at one-tenth the dose. Codeine is a prodrug that must be converted to morphine by the enzyme cytochrome P450 2D6. The key distinction here is between efficacy (Emax, which is the same) and potency (EC50, which differs), not between agonist categories.

Correct Answer

C — Buprenorphine has a lower EC50 and a lower Emax than morphine

Rationale

Buprenorphine is a high-affinity partial agonist at the mu-opioid receptor. Its very high receptor affinity means it achieves half-maximal effect at a low concentration — a low EC50, indicating high potency. As a partial agonist, however, each buprenorphine-receptor complex generates less downstream signal than a full agonist-receptor complex would, so even at concentrations that fully occupy all available receptors, the maximum response falls short of the system maximum produced by full agonists such as morphine — a lower Emax, indicating lower efficacy. This combination of high potency and lower efficacy is the defining pharmacodynamic profile of a partial agonist with high receptor affinity.

Correct Answer

B — Drug X is more efficacious; Drug Y is more potent

Rationale

Efficacy is defined by Emax — the maximum response a drug can produce at saturating concentrations. Drug X produces a plateau of 80 units versus Drug Y's plateau of 40 units, so Drug X has the higher Emax and is therefore more efficacious. Potency is defined by EC50 — the concentration required to produce half the maximum response. Drug Y reaches its plateau at lower concentrations, meaning its EC50 is lower, making it more potent. These two properties are independent: a drug can be highly potent (achieving its maximum at low concentrations) while having low efficacy (that maximum is itself low), as is the case with Drug Y here. The clinical implication is that choosing between drugs requires knowing which property — efficacy or potency — matters more for the clinical situation at hand.

Correct Answer

D — The dose at which 50% of the population exhibits the defined sedative endpoint

Rationale

A quantal dose-response curve measures an all-or-none endpoint — a response that is either present or absent — across a population of subjects. The median effective dose is derived from this population distribution and represents the dose at which exactly half the subjects in the study exhibit the defined endpoint. It is a population statistic, not a measurement in any individual subject. This is distinct from the graded dose-response curve, which measures the magnitude of a continuous response in a single preparation and yields an EC50 — the concentration producing 50% of the maximum effect in that preparation. The median effective dose and EC50 both describe potency in a broad sense but are measured differently and are not interchangeable.

Correct Answer

A — Drug A is more potent than Drug B, and the two drugs have equal efficacy

Rationale

On a log dose-response graph, a leftward shift of the curve indicates a lower EC50 — the drug produces half its maximum effect at a lower concentration, which is the definition of greater potency. Drug A's leftward position means it achieves any given response level at a lower dose than Drug B. Because both curves reach the same maximum plateau, the two drugs have identical Emax values and therefore equal efficacy. Potency and efficacy are independent properties. The leftward shift represents a potency difference only; if there were also an efficacy difference, the plateau heights would differ. Recognizing this pattern on a dose-response graph — same plateau, different horizontal position — is the standard way potency differences are visualized.

Correct Answer

C — Drug X has a higher therapeutic index and a wider safety margin than Drug Y

Rationale

The therapeutic index is calculated as the median lethal dose divided by the median effective dose. Drug X: 500 divided by 50 equals a therapeutic index of 10. Drug Y: 300 divided by 100 equals a therapeutic index of 3. Drug X's therapeutic index of 10 is more than three times that of Drug Y, indicating a wider separation between the effective and lethal dose ranges and therefore a greater safety margin. A lower median effective dose means the drug is more potent — it produces its effect at a lower dose — but potency does not determine safety margin. What determines safety margin is the ratio of lethal to effective dose, not the absolute value of either alone.

Correct Answer

B — Potassium and digoxin compete for the same binding site on sodium-potassium ATPase; low potassium increases digoxin binding and inhibition

Rationale

Digoxin exerts its effect by inhibiting sodium-potassium ATPase in cardiac cells. Potassium ions and digoxin bind at overlapping sites on the extracellular face of this enzyme. When serum potassium is low, less potassium occupies its binding site on the ATPase, allowing more digoxin to bind and producing greater enzyme inhibition at the same digoxin plasma concentration. This pharmacodynamic interaction shifts the digoxin concentration-effect relationship, pushing a patient with a previously safe digoxin level into the toxic range. This is a pharmacodynamic interaction — the effect of digoxin changes at the same plasma concentration — rather than a pharmacokinetic one. Monitoring and correcting potassium levels is a core component of safe digoxin management.

Correct Answer

D — Signal amplification downstream of the receptor saturates the effector pathway before half the receptors are occupied, so the half-maximal functional response is reached at a lower concentration than that needed to occupy half the receptors

Rationale

In a tissue with receptor reserve, activated receptors trigger highly amplified downstream signaling cascades — each activated receptor can activate multiple G proteins, which activate multiple effector enzymes, generating many second messenger molecules. Because of this amplification, the effector system may reach 50% of its maximum output when only a small fraction of receptors are occupied. The drug concentration needed to produce that half-maximal functional response is therefore lower than the concentration needed to occupy half the receptors. This is why the functional EC50 is less than the binding Kd in tissues with spare receptors. The discordance is a sign of amplification, not of stronger binding in functional assays.

Correct Answer

A — The curve shifts to the right but the maximum response is preserved, because the remaining receptors are still sufficient to saturate the effector pathway

Rationale

Receptor reserve means the tissue contains more receptors than are needed to produce the maximum response. When an irreversible antagonist eliminates 40% of receptors, the remaining 60% still exceed the minimum number required to saturate the downstream effector pathway. The maximum response is therefore preserved. However, because fewer total receptors are available, a higher agonist concentration is needed to occupy enough of them to reach each level of response — the curve shifts rightward. Only when enough receptors have been permanently inactivated to push the remaining active pool below the minimum needed for a full response does Emax begin to fall. Receptor reserve acts as a buffer protecting the maximum response against irreversible receptor loss.

Correct Answer

C — Brainstem respiratory control centers have less mu-opioid receptor reserve than nociceptive pathways, so buprenorphine's lower per-receptor signal fails to saturate the effector in the brainstem but can in pain pathways

Rationale

As a partial agonist, buprenorphine generates less signal per occupied receptor than a full agonist would. Whether that reduced signal still produces a full tissue response depends on the receptor reserve in each tissue. Nociceptive pain pathways operate with sufficient opioid receptor reserve that even buprenorphine's attenuated per-receptor signal, when summed across the occupied receptor pool, can drive the effector pathway to produce meaningful analgesia. Brainstem respiratory control centers have relatively limited opioid receptor reserve, so buprenorphine's lower per-receptor output is unable to drive those pathways to maximum activity regardless of dose — producing a genuine ceiling effect on respiratory depression. This tissue-dependence of partial agonist behavior is a clinically important consequence of receptor reserve differences across organ systems.

Correct Answer

D — Ibuprofen reduces renal prostaglandin synthesis, decreasing renal lithium clearance and raising serum lithium into the toxic range

Rationale

Lithium's narrow therapeutic index means that even modest increases in plasma concentration can cross from therapeutic into toxic. Nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase and reduce renal prostaglandin synthesis, which normally maintains renal blood flow and glomerular filtration. When renal prostaglandins are suppressed, renal lithium clearance falls, and lithium accumulates to toxic levels even without any change in lithium dose. This is a well-recognized and clinically important drug interaction. The symptoms — tremor, nausea, and confusion — are hallmarks of lithium toxicity. Lithium is not protein-bound, so displacement is not the mechanism. The interaction operates through reduced renal elimination, not through altered absorption or volume of distribution.

Correct Answer

B — Furosemide has a higher maximum diuretic effect than hydrochlorothiazide, allowing greater fluid removal when maximum diuresis is needed

Rationale

The clinical decision here is driven by efficacy — specifically, which drug can produce the maximum diuretic effect the situation demands. Furosemide acts on the thick ascending limb of the loop of Henle, which handles approximately 25% of filtered sodium, giving it a substantially higher Emax for sodium and water excretion than hydrochlorothiazide, which acts on the distal tubule. In severe heart failure with significant volume overload, hydrochlorothiazide's lower Emax ceiling is simply insufficient to produce the degree of diuresis needed. Switching to furosemide addresses the efficacy gap. Potency — which drug achieves its effect at a lower concentration — is not the relevant consideration here. Furosemide's half-life is actually shorter than that of many thiazides.

Correct Answer

A — Hypokalemia caused by diarrhea increases digoxin binding to its target enzyme, producing greater inhibition at the same plasma concentration

Rationale

This is a pharmacodynamic interaction, not a pharmacokinetic one — the digoxin level has not changed, but the effect at that level has intensified. Potassium and digoxin compete for overlapping binding sites on the extracellular face of sodium-potassium ATPase. When potassium is low from diarrhea-related losses, less potassium competes with digoxin for enzyme binding, so digoxin occupies and inhibits more enzyme molecules at the same plasma concentration. The clinical threshold for toxicity — arrhythmias, nausea, visual changes — is crossed at a digoxin level that was previously safe. This scenario illustrates why the effective therapeutic range for digoxin is not a fixed concentration but depends on serum potassium, and why electrolyte monitoring is a mandatory component of digoxin management.

Correct Answer

C — Platelets lack a nucleus and cannot synthesize new cyclooxygenase to replace inactivated enzyme, while endothelial cells can regenerate their enzyme; additionally, platelet thromboxane synthesis has no cyclooxygenase enzyme reserve to speak of

Rationale

Two mechanisms converge to produce platelet selectivity at low aspirin doses. First, platelets are anucleate — they cannot synthesize new proteins, so aspirin-inactivated cyclooxygenase is gone for the platelet's entire lifespan of 7 to 10 days. Vascular endothelial cells are nucleated and can synthesize replacement cyclooxygenase within hours of aspirin exposure, rapidly restoring prostacyclin production. Second, the thromboxane A2 pathway in platelets operates with very little cyclooxygenase enzyme reserve — even partial enzyme inhibition substantially impairs thromboxane synthesis and platelet aggregation. The prostacyclin pathway in endothelium has relatively more enzyme reserve, requiring more complete inhibition to suppress prostacyclin output. The combination of irreversibility, inability to regenerate enzyme, and lack of enzyme reserve makes platelets uniquely sensitive to even low aspirin doses.